Lactoferrin as Immune-Enhancement Strategy for SARS-CoV-2 Infection in Alzheimer’s Disease Patients
Coronavirus 2 (SARS-CoV2) (COVID-19) causes severe acute respiratory syndrome. Severe illness of COVID-19 largely occurs in older people and recent evidence indicates that demented patients have higher risk for COVID-19. Additionally, COVID-19 further enhances the vulnerability of older adults with...
Main Authors: | Fernando Bartolomé, Luigi Rosa, Piera Valenti, Francisco Lopera, Jesús Hernández-Gallego, José Luis Cantero, Gorka Orive, Eva Carro |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-04-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.878201/full |
Similar Items
-
Standardizing salivary lactoferrin measurements to obtain a robust diagnostic biomarker for Alzheimer's disease
by: Fernando Bartolome, et al.
Published: (2021-01-01) -
Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin
by: Eva Carro, et al.
Published: (2017-01-01) -
Salivary Lactoferrin Expression in a Mouse Model of Alzheimer’s Disease
by: Desiree Antequera, et al.
Published: (2021-09-01) -
Lactoferrin in cerebrospinal fluid and saliva is not a diagnostic biomarker for Alzheimer's disease in a mixed memory clinic population
by: Helena Sophia Gleerup, et al.
Published: (2021-05-01) -
Salivary lactoferrin is associated with cortical amyloid-beta load, cortical integrity, and memory in aging
by: Lucia Reseco, et al.
Published: (2021-09-01)